Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Zadaxin + standard chemotherapy in metastatic or recurrent EGFR/ALK-negative non-small cell lung cancer
ChiCTR2400091368Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Apr 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, thymosin alpha 1, carboplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Objective response rate. Started Apr 2021; status: recruiting.
02
Drugs
tislelizumabthymosin alpha 1carboplatinpemetrexedpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400091368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091368.